Sk Biopharmaceuticals Co Ltd (326030) - Total Liabilities

Latest as of March 2026: ₩388.37 Billion KRW ≈ $263.19 Million USD

Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has total liabilities worth ₩388.37 Billion KRW (≈ $263.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sk Biopharmaceuticals Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Sk Biopharmaceuticals Co Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Sk Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sk Biopharmaceuticals Co Ltd (326030) total assets.

Sk Biopharmaceuticals Co Ltd Competitors by Total Liabilities

The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
PBF Energy Inc NYSE:PBF	USA	$7.68 Billion
Xiamen Faratronic Co Ltd SHG:600563	China	CN¥2.47 Billion
Hyundai Motor Co Pref KO:005387	Korea	₩229.09 Trillion
Dun & Bradstreet Holdings Inc. NYSE:DNB	USA	$5.41 Billion
Turkcell Iletisim Hizmetleri A.S F:TUL1	Germany	€350.33 Billion
Anhui Yingliu SHG:603308	China	CN¥8.31 Billion
Holy Stone Enterprise Co Ltd TW:3026	Taiwan	NT$5.79 Billion
Jiangxi Zhengbang Technology Co Ltd SHE:002157	China	CN¥9.41 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Sk Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 326030 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.49	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.42	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sk Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sk Biopharmaceuticals Co Ltd (2016–2025)

The table below shows the annual total liabilities of Sk Biopharmaceuticals Co Ltd from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩372.04 Billion ≈ $252.13 Million	-19.62%
2024-12-31	₩462.83 Billion ≈ $313.65 Million	+15.07%
2023-12-31	₩402.22 Billion ≈ $272.58 Million	+15.69%
2022-12-31	₩347.68 Billion ≈ $235.62 Million	+74.31%
2021-12-31	₩199.46 Billion ≈ $135.17 Million	+64.61%
2020-12-31	₩121.17 Billion ≈ $82.12 Million	-20.33%
2019-12-31	₩152.10 Billion ≈ $103.07 Million	+312.12%
2018-12-31	₩36.91 Billion ≈ $25.01 Million	-27.81%
2017-12-31	₩51.12 Billion ≈ $34.65 Million	+10.64%
2016-12-31	₩46.21 Billion ≈ $31.31 Million	--

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$4.08 Billion

₩6.02 Trillion KRW

Market Cap Rank

#4098 Global

#92 in Korea

Share Price

₩76900.00

Change (1 day)

-0.90%

52-Week Range

₩74600.00 - ₩140700.00

All Time High

₩217000.00